RG7388 has been shown to activate wild-type p53, evidenced by p53 stabilisation accompanied by the induction of p21 and MDM2 expression and the induction of p53-dependent apoptosis in different cell types [22,23,24,25], including primary CLL cells [26]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.